Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
AIDS Research and Human Retroviruses|October 29, 2021
HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021Fatima Laher, Simone I Richardson, Philip Smith, et al.Cell Reports. Medicine|April 27, 2022
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concernDale Kitchin, Simone I Richardson, Mieke A van der Mescht, et al.Cell Reports. Medicine|January 5, 2023
Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variantSimone I Richardson, Prudence Kgagudi, Nelia P Manamela, et al.Cell Host & Microbe|October 24, 2021
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent mannerRoanne Keeton, Simone I Richardson, Thandeka Moyo-Gwete, et al.Cell Reports. Medicine|May 31, 2021
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functionsAndrea R Shiakolas, Kevin J Kramer, Daniel Wrapp, et al.Biorxiv : the Preprint Server for Biology|January 5, 2021
Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functionsAndrea R Shiakolas, Kevin J Kramer, Daniel Wrapp, et al.Biorxiv : the Preprint Server for Biology|February 3, 2025
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivityParker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, et al.Structure (London, England : 1993)|September 26, 2024
Discovery and characterization of a pan-betacoronavirus S2-binding antibodyNicole V Johnson, Steven C Wall, Kevin J Kramer, et al.The Lancet. Infectious Diseases|October 23, 2022
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trialShabir A Madhi, Gaurav Kwatra, Simone I Richardson, et al.Plos Pathogens|September 18, 2024
Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral familiesMatthew J Vukovich, Andrea R Shiakolas, Jared Lindenberger, et al.Pageof 5